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Abstract—A simple, efficient, and environmentally friendly protocol for the synthesis of 1,3,5-triarylpyrazole in [bimm][PF6] ionic 
liquid mediated by Cu(OTf)2 is described. The reaction protocol gave 1,3,5-triarylpyrazoles in good to high yields (71-82%) via a one-pot 
addition–cyclocondensation between hydrazines and chalcones, and oxidative aromatization without requirement for an additional 
oxidizing reagent. The catalyst can be reused up to four cycles without much loss in the catalytic activity. The pyrazoles (4a-o) and 
pyrazolines (3a-n) were evaluated for antiproliferative activity in SK-OV-3, HT-29, and HeLa human cancer cells lines. Among all 
compounds, 3b inhibited cell proliferation of HeLa cells by 80% at a concentration of 50 µM. 
Pyrazoles and their derivatives are well recognized 
as an important class of heterocyclic compounds that 
have been found with extensive use in the 
pharmaceutical, material, and agrochemical industries.1 
Compounds containing pyrazole moiety have exhibited 
diverse biological activities. For example, 4-substituted 
1,5-diaryl-1H-pyrazole-3-carboxylate derivatives can 
act as cannabinoid-1 (CB1) receptor antagonists,2-7 Iκβ 
kinase β (IKKβ or IKK-2) inhibitors,8 and anti-
inflammatory agents.9 Pyrazole derivatives have been 
shown to have good binding affinity towards estrogen 
receptor.10-12 Some of the pyrazole derivatives have 
been reported to possess antidepressant, 
anticonvulsant,13 anti-inflammatory, and arthritics14 
activities. Pyrazole scaffold constitutes the basic 
framework of several drug molecules such as celecoxib 
(a non-steroidal anti-inflammatory drug)14 and 
rimonabant (an anorectic antiobesity drug) (Figure 1). 
 
Figure 1. Chemical structures of drug molecules, celecoxib and 
rimonabant containing pyrazole scaffold.  
Because of their diverse bioactivities, pyrazoles have 
received considerable attention of chemists. Thus, a 
number of synthetic strategies have been developed for 
their synthesis.15, 16 The most common approach for 
synthesis of substituted pyrazoles is the condensation of 
α,β-unsaturated carbonyl compounds with hydrazines. 
However, this strategy results in the formation of 4,5-
dihydro-1H-pyrazoles (pyrazolines) that need to be 
further oxidized to corresponding pyrazoles. For this 
oxidative aromatization of pyrazolines to pyrazoles, 
various reagents have been employed such as I217, 
Bi(NO3)3. 5H2O18, MnO219, DDQ20, Pd/C21, NaOEt22, 
PhI(OAc)223, and TBBDA24. However, many of these 
oxidative methods suffer from relatively high oxidant 
loading, use of strong oxidants and chlorinated organic 
solvents, harsh conditions, poor yields, and longer 
reaction time. Thus, the development of 
environmentally benign processes with the use of 
alternative solvents such as ionic liquids in place of 
organic solvent and a catalytic amount of ecofriendly 
catalysts that avoid harsh oxidizing reagents are 
desirable. 
As part of our ongoing work on the development of 
novel reaction methodologies using metal triflates,25-27 
and evaluation of small molecules as anticancer 
agents,27-30 herein we report copper (II) triflate-mediated 
protocol for the synthesis of pyrazoles by one-pot 
reaction of hydrazines with α,β-unsaturated ketones in 
1-butyl-3-methylimidazolium hexafluorophosphate 
([bmim][PF6]) ionic liquid (Scheme 1) and evaluation of 
antiproliferative activity against different cancer cell 
lines. 
In the standardization experiment, when 4-tert-
butylphenylhydrazine hydrochloride (2) and 1,2-
diphenylprop-2-en-1-one (1) were reacted in ethanol at 
130 °C in the presence of Cu(OTf)2 (20 mole %), 1-(4-
tert-butylphenyl)-3,5-diphenyl-4,5-dihydro-1H-pyrazole 
(3a) was obtained in 62% yield (Table 1, entry 8). 
 Further optimization of reaction condition was carried 
out by changing solvents, catalysts, and catalyst 
loading. As shown in Table 1, the use of 20 mol% 
Cu(OTf)2 in [bmim][PF6] gave the desired product 4a in 
excellent yield (82%) (Table 1, entry 2). When 
Cu(OTf)2 was changed with other catalysts such as 
pTSA, Sc(OTf)3, Ce(OTf)3, Zn(OTf)2, AgOTf, or 
Yb(OTf)3, a mixture of 3a and 4a was observed. Use of 
Ce(OTf)3 in [bmim][PF6] resulted in 75% of 3a along 
with 10% of 4a whereas pTSA in [bmim][PF6] gave 
69% of 3a (Table 1, entry 11-12). There was not much 
increase in yield of 4a on changing the amount of 
Cu(OTf)2 from 20 mol% to 30 mol%. However, 
reducing the amount of Cu(OTf)2 to 10 mol% decreased 
the yield of 4a to 64% along with the formation of 3a in 
15% (Table 1, entries 1-3). These data indicate that 
Cu(OTf)2 was involved in aerobic oxidation of 3a to 4a. 
It is necessary to mention that 4a was not formed in the 
absence of Cu(OTf)2 in [bmim[PF6] ionic liquids, and 
only 3a was isolated along with starting material. 
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Scheme 1. Synthesis of substituted 1,3,5-triarylpyrazoles. 
Table 1. Optimization of reaction conditions for the synthesis of 
4a.a  
S. 
No Catalyst 
Mol 
(%) Solvent 
Yield 
(3a) (%)b 
Yield 
(4a) (%)b 
1 Cu(OTf)2 10 [bmim][PF6] 15 64c 
2 Cu(OTf)2 20 [bmim][PF6] - 82 
3 Cu(OTf)2 30 [bmim][PF6] - 84 
4 Cu(OTf)2 20 [bmim][BF4] 35 50 
5 Cu(OTf)2 20 [bmim][Br] 50 21 
6 Cu(OTf)2 20 DMSO - 15 
7 Cu(OTf)2 20 DMF - 33 
8 Cu(OTf)2 20 Ethanol 62d - 
9 Cu(OTf)2 20 PEG 60 - 
10 Sc(OTf)3 20 [bmim][PF6] 61 19 
11 Ce(OTf)3 20 [bmim][PF6] 75 10 
12 pTSA 20 [bmim][PF6] 69 - 
13 Zn(OTf)2 20 [bmim][PF6] 55 30 
14 AgOTf 20 [bmim][PF6] 15 65 
15 Yb(OTf)3 20 [bmim][PF6] 58 22 
aReaction condition: Chalcone (1.0 mmol), arylhydrazine (1.2 
mmol), 130 °C, 2 h.  
bIsolated yield.  
cOnly 20% of 3a was formed after 30 min in the absence of 
Cu(OTf)2 under similar conditions. 
dReflux condition. 
The structure of compound 4a was confirmed by 1H 
NMR, 13C NMR, and high-resolution mass 
spectroscopy. In the 1H NMR spectra, a singlet was 
observed at δ 6.81 for the proton at C-4 position of 
pyrazole ring along with other protons on aryl 
substituents. In 13C NMR, a peak appeared at δ 104.97 
for the C-4 carbon of pyrazole ring. HRMS of 4a 
showed a peak at m/z for molecular ion. Thus, NMR 
and mass analysis confirmed that the product was 
pyrazole and not pyrazoline.  
To explore the synthetic scope and versatility of the 
protocol, a series of aryl hydrazines 2 were reacted with 
different α,β-carbonyl compounds (1) under the optimal 
reaction conditions. The results are summarized in 
Table 2. Various groups, such as F, Cl, NO2, OCH3, CH3 
and -C(CH3)3 on aryl hydrazines and chalcones were 
well tolerated in these conditions affording the 
corresponding 1,3,4-substituted pyrazoles (4a-o) in 
good to high yields (71–82%). 
Table 2. Synthesized 1,3,5-triarylpyrazoles (4a-o). 
 
Compd R1 R2 R3 
Time 
(Min.) 
Yield 
(%)a 
4a H H 4-C(CH3)3 120 82b 
4b H H 2-CH3 120 81 
4c H H 3,4-Cl 180 80 
4d H H 3-Cl, 4-CH3 150 72 
4e 4-OMe H 3,4-Cl 120 71 
4f 4-OMe H 3-Cl, 4-CH3 120 77 
4g 3-OMe 4-CH3 3,4-Cl 120 79 
4h 4-CH3 4-CH3 3,4-Cl 120 74 
4i 4-CH3 4-CH3 3-Cl, 4-CH3 120 77 
4j 4-CH3 4-CH3 4-C(CH3)3 105 77 
4k 2-F 4-Cl 4-C(CH3)3 120 84 
4l 2-F 4-Cl 2-CH3 120 82 
4m 4-NO2 4-OMe 4-C(CH3)3 60 75 
4n 4-NO2 4-OMe 3-Cl, 4-CH3 60 81 
4o H H 4-OMe 90 78 
aIsolated yield 
bIn four consecutive recycle experiment 4a was observed in 82, 
80, 78, and 79% yield, respectively.  
By monitoring the model reaction between 1,2-
diphenylprop-2-en-1-one (1) and tert-butylphenyl-
hydrazine hydrochloride (2) in the presence of 20 mol% 
Cu(OTf)2 in [bmim][PF6] at different time interval it 
was found that in first 30 minutes pyrazoline (3a) was 
the major product, which got oxidized to pyrazole in the 
reaction as time progresses. We thus decided to 
synthesize the pyrazolines using this protocol in order to 
evaluate them in our biological assay. The reaction of 1 
 and hydrazines 2 afforded 1,3-pyrazolines 3a–o via a 
one-pot addition–cyclocondensation process in good to 
high yields (60-84%). Several α,β-unsaturated carbonyl 
compounds with both electron-rich and electron-
deficient arenes were successfully applied to this 
reaction. The results of pyrazoline synthesis are 
summarized in Table 3. The chemical structures of all 
synthesized compounds were elucidated by 1H NMR, 
13C NMR, and high-resolution mass spectroscopy 
(Supporting information).  
Table 3. Synthesized 1,3,5-triarylpyrazolines (3a-n). 
 
Compd R1 R2 R3 
Time 
(Min.) 
Yield 
(%)a 
3a H H 4-C(CH3)3 120 84 
3b H H 2-CH3 120 66 
3c H H 3,4-Cl 90 77 
3d H H 3-Cl, 4-CH3 180 68 
3e 4-OMe H 3,4-Cl 150 72 
3f 4-OMe H 3-Cl, 4-CH3 120 78 
3g 3-OMe 4-CH3 3,4-Cl 120 60 
3h 4-CH3 4-CH3 3,4-Cl 120 72 
3i 4-CH3 4-CH3 3-Cl, 4-CH3 120 74 
3j 4-CH3 4-CH3 4-C(CH3)3 120 79 
3k 2-F 4-Cl 4-C(CH3)3 105 63 
3l 2-F 4-Cl 2-CH3 120 65 
3m 4-NO2 4-OMe 4-C(CH3)3 120 72 
3n 4-NO2 4-OMe 3-Cl, 4-CH3 60 80 
aIsolated yield 
Based on the intermediate formed (3a) and structure 
of the product (4a) as analyzed by NMR, the reaction is 
proposed to proceed through the sequential steps as 
shown in Scheme 2. The first step is believed to be 1,4-
addition of hydrazine to chalcone mediated by copper 
(II) triflate. The 3-hydrazino ketone undergoes 
nucleophilic addition followed by elimination to give 
1,3,5-triarylpyrazolines derivative. 1,3,5-Triaryl-
pyrazolines derivatives undergo oxidative aromatization 
in the presence of copper (II) triflate to yield 
corresponding 1,3,5-triarylpyrazole derivatives. It 
appeared that ionic liquid helps in stabilization of 
charged intermediate generated by coordination of 
Cu(OTf)2 to carbonyl of chalcone and thereby increases 
electrophilicity of chalcone. 
Further, we investigated the possibility of recycling 
of the catalyst. After performing the first cycle, the 
product was extracted with ethyl acetate/hexane 
mixture, and Cu(OTf)2 in ionic liquid was properly 
dried under pressure. Furthermore, the fresh chalcone 
and 4-tert-butyl phenylhydrazine hydrochloride were 
charged under same conditions. The above procedure 
was repeated four times to give 4a in high yields (82, 
80, 78, and 79%) without much loss of catalytic 
activity. 
 
Scheme 2. Proposed mechanism for synthesis of 1,3,5-
triarylpyrazole. 
To evaluate the anticancer activity of synthesized 
compounds, all derivatives (4a-o and 3a-n) were 
evaluated for their inhibitory activity on the 
proliferation of human ovarian adenocarcinoma (SK-
OV-3), human colon adenocarcinoma (HT-29), and 
human cervical adenocarcinoma (HeLa) cells. 
Doxorubicin (Dox) and DMSO were used as positive 
and negative controls, respectively. The antiproliferative 
activity results of compounds 4a-o and 3a-n at 50 µM 
after 72 h incubation are shown in Figures 2 and 3, 
respectively.  
Figure 2 shows that among all 1,3,5-triarylpyrazoles 
derivatives, compounds 4c, 4e, 4f, 4g, 4h, 4i, and 4k 
inhibit the proliferation of HeLa cells by 50%, 55%, 
45%, 39%, 54%, 42%, and 50%, respectively. However, 
they did not exhibit significant inhibitory potency in 
HT-29 and SK-OV-3 cells. 
 
Figure 2. Antiproliferative activity of 4a-o.  
 
  
Figure 3. Antiproliferative activity of 3a-n. 
Furthermore, 1,3,5-triarylpyrazolines derivatives 
(3a-n) were examined for their inhibitory activity 
against the proliferation of HT-29, SK-OV-3, and HeLa 
cells. Most of the derivatives showed cell specific 
dependent inhibitory activity. Several derivatives 
showed high to weak antiproliferative activity against 
HeLa cells after 72 h incubation. Compounds 3c, 3d, 3e, 
3k, 3l, and 3m inhibited the proliferation of HeLa cells 
by 62%, 50%, 35%, 58%, 23%, and 40%, respectively. 
2-Methylsubstituted compound 3b showed the highest 
potency by 80% inhibition of HeLa cells. 1,3,5-
Triarylpyrazolines derivative showed modest to weak 
potency in SK-OV-3 and HT-29 cells. Among all 
derivatives, compound 3b showed comparable potency 
to Dox in HeLa cells. Further modification on the 
chemical structure of this derivative could lead to the 
synthesis of a promising candidate that selectively target 
HeLa cells.  
In summary, we have developed a simple and 
efficient and environmentally friendly protocol for the 
synthesis of 1,3,5-triarylpyrazole in [bimm][PF6] ionic 
liquid mediated by Cu(OTf)2. The reaction protocol 
exhibited tolerance with different functional groups, 
generating pyrazoles in good to high yields (71-82%) 
without any requirement for additional reagent for the 
oxidation of in situ generated pyrazolines. The catalyst 
can be reused up to five cycles without much loss in 
catalytic activity. The pyrazoles (4a-o) and pyrazolines 
(3a-n) were evaluated for antiproliferative activity. 
Compound 3b inhibited cell proliferation of HeLa cells 
by 80% at a concentration of 50 µM. All other 
synthesized derivatives exhibited a modest inhibition 
against the proliferation of SK-OV-3, HT-29 and HeLa 
cells. Further structure-activity relationship studies are 
required for optimizing antiproliferative activities of 
these classes of compounds. 
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